Investing in Innovation: Lyla Bibi’s Perspective on Biotech Markets
In this episode of Clinical Trialblazers, Lyla Bibi, Partner at Goldman Sachs and Head of Healthcare Equity Capital Markets, shares her impactful career journey focused on helping bring cutting-edge therapies to life by bridging capital and science. Tune in as she offers a behind-the-scenes look into the nuances of biotech investment in today’s competitive landscape, emphasizing the importance of a clear value proposition, the enduring power of trust in leadership, and the essential characteristics of successful biotech CEOs. Beyond the science and market trends, Lyla offers valuable insights on balancing a demanding career with a full personal life and her optimistic outlook on the future of scientific funding.
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026